ArQule, Inc. (NASDAQ:ARQL)
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
pchop123
(76.49)
Submitted: 5/10/2013 12:38:52 PM :
Start Price:
$2.80
ARQL Score:
-3.21
optomistic at this price level
Recs
NuclearSteve
(54.51)
Submitted: 4/12/2013 2:08:16 PM :
Start Price:
$2.79
ARQL Score:
-5.63
Baker brothers increased their holding.
Recs
zzlangerhans
(99.77)
Submitted: 2/25/2013 6:47:13 AM :
Start Price:
$2.40
ARQL Score:
+5.58
ArQule has fallen off the oncology A-list after the failure of tivatinib in phase III trials for NSCLC, but the company has a solid cash runway and a controlled burn due to strong partnership deals. The stock has been in decline despite the beginning of enrollment in the phase III trial of tivatinib in hepatocellular carcinoma. Burned traders could be forgiven for wanting to give ArQule a pass this time around, but eventually the street will notice the low enterprise value for a progressing phase III oncology trial. Even a small chance at success in a subpopulation is worth more than what ArQule is being spotted now.
Recs
MrOneHundred
(33.95)
Submitted: 2/24/2013 3:56:22 AM :
Start Price:
$2.41
ARQL Score:
+5.98
I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock been this low. Its price has climbed up to as high as $10 in times past! With the company's current pipeline, a plausible economic crisis (something this sector can be relatively immune to and could therefore draw investors), and add in the fact that ArQule is presenting at the RBC Capital Markets Global Healthcare Conference coming this Tuesday... it seems likely that something positive, no matter how minute, will likely send this stock up quick. Dilution, or other bad things could happen, but I'm having a difficult time seeing it happen with this company. The fundamentals on this stock are shaky, though. This is not without risk.
Recs
scottbiddle64
(< 20)
Submitted: 1/14/2013 11:58:24 PM :
Start Price:
$2.50
ARQL Score:
+2.91
Failure on clinical trials
Recs
portefeuille
(99.78)
Submitted: 11/25/2010 1:12:50 PM :
Start Price:
$3.95
ARQL Score:
-115.92
currently 90 shares in my portfolio.
Recs
Recs
quinpeung
(53.09)
Submitted: 3/31/2010 1:19:25 PM :
Start Price:
$6.45
ARQL Score:
-99.20
Mr. negative here, uncharacteristically giving a green thumb to a biotech stock. But if the phase III results are solid for the combination of ARQ 197 and Tarceva, and given Astellas' current pursuit of OSIP (markets Tarceva), the future looks bright for ARQL.
Recs
wakoma
(< 20)
Submitted: 9/29/2008 7:46:43 AM :
Start Price:
$3.15
ARQL Score:
-55.45
Bought based on feedback from a couple of friends in the oncology industry. Small position. yrs away from knowing the outcome. Some smart money likes what they see. Who knows. Pretty much dead money for the near term
Recs
Dapperatom
(< 20)
Submitted: 5/14/2008 1:54:31 PM :
Start Price:
$4.23
ARQL Score:
-56.15
I like the below $10 price and its potential for a good return.
Recs
spicebyr
(94.00)
Submitted: 4/27/2008 9:42:21 AM :
Start Price:
$3.84
ARQL Score:
-51.42
This issue has too many LARGE investment banks/investors putting $$$ into it. Currently (late April 2008) it has been beaten to a point where an entry at this level will "probably" provide 100% ROI. Everyone is responsible for their own due diligence. This is one that has GREAT potential!!!
Recs
Fundzrlow
(< 20)
Submitted: 4/24/2008 11:40:43 AM :
Start Price:
$3.85
ARQL Score:
-53.04
I think this an upcoming stock, although it fluctuates it is a strong stock.
Recs
zacprince
(64.44)
Submitted: 9/24/2007 8:41:15 PM :
Start Price:
$7.50
ARQL Score:
-78.90
best wall street player likes it, there probably smarter than me, so im going for it.
Recs
myersfield
(< 20)
Submitted: 8/27/2007 2:35:38 PM :
Start Price:
$7.86
ARQL Score:
-83.62
2 hottest new best in class cancer drug programs in phase 2: c-met and E2F1 checkpoint activators should lead to good deals, broad application, high efficiency, negligible side effects.
Recs
mcmartinson
(91.79)
Submitted: 8/1/2007 3:39:16 PM :
Start Price:
$5.53
ARQL Score:
-70.99
Safety profile of their C-Met inhibitor should win out over the Exelixis inhibitor in the clinic.
Recs
barrettfodder
(60.42)
Submitted: 6/21/2007 9:59:17 AM :
Start Price:
$7.62
ARQL Score:
-80.29
If the next phase of clinical trials goes well. This company will be set for the remainder of its life. Worth a look
Recs
aclowe01
(59.25)
Submitted: 6/14/2007 11:23:18 AM :
Start Price:
$7.84
ARQL Score:
-80.23
The Cancer Survival Protein modulation program
is a home run for this small growing company.
Recs
iceman7403
(58.04)
Submitted: 5/7/2007 5:51:45 PM :
Start Price:
$9.08
ARQL Score:
-86.59
takeover candidate
Recs
2tal
(< 20)
Submitted: 4/10/2007 1:50:12 PM :
Start Price:
$8.40
ARQL Score:
-88.88
A biotech that is starting to hit its stride. The stock is starting to move regularly and in the right direction.
Recs
kostian
(53.79)
Submitted: 3/26/2007 11:11:23 PM :
Start Price:
$7.39
ARQL Score:
-85.69
just gonna try getting in at this hoping for something good
at $7.30
might be a short or might go long.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 25 : 1 2 Next »